TOKYO and BOSTON, July 21, 2020 /PRNewswire/ -- and July 22, 2020 - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) and Biofourmis, a Boston-based digital therapeutics company, announced that they have ...

Japanese pharmaceutical giant Chugai and Boston-based digital therapeutics company Biofourmis announced that they have partnered to develop a digital solution for the objective assessment of pain ...

Waltham — January 25, 2024 — A newly developed neural network is highly accurate in identifying key landmarks important in breast surgery – opening the potential for objective assessment of breast ...

The degree to which a surgical patient's subconscious processing of pain, or "nociception," is properly managed by their anesthesiologist will directly affect the degree of post-operative drug side ...

Quality Matters Standard 3.1 is one of the alignment standards and is an essential (required) standard. It states, “The assessments measure the achievement of the stated learning objectives or ...

Identifying and validating disease-causing genes that are viable as drug targets is a key challenge in drug discovery. Large-scale multi-omics initiatives are deepening our understanding of cancer and ...